Gata3 antagonizes cancer progression in pten-deficient prostates

Human Molecular Genetics

Volumn 22, Issue 12, 2013, Pages 2400-2410

  Nguyen, Alana H T ^a   Tremblay, Mathieu ^a   Haigh, Katharina ^b,c   Hervékoumakpayi, Ismaël ^d   Paquet, Mariléne ^f   Pandolfi, Pier Paolo ^g   Mes Masson, Anne Marie ^e   Saad, Fred ^d,e   Haigh, Jody J ^b,c   Bouchard, Maxime ^a  

^a MCGILL UNIVERSITY   (Canada)

^b GHENT UNIVERSITY   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e Institut du Cancer de Montreal   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEASOME; PROTEIN KINASE B; TRANSCRIPTION FACTOR GATA 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME SUBUNIT; GAIN OF FUNCTION MUTATION; GENE INACTIVATION; HORMONE SENSITIVITY; HUMAN; HUMAN TISSUE; LOSS OF FUNCTION MUTATION; MALE; MOUSE; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

ANIMALS; DOWN-REGULATION; FEMALE; GATA3 TRANSCRIPTION FACTOR; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROSTATE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84878511490     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt088     Document Type: Article

References (35)

1. Feldman, B.J. and Feldman, D. $(2001) The development of androgen-independent prostate cancer. Nat. Rev. Cancer, 1, 34-45.
2. Shen, M.M. and Abate-Shen, C. $(2007) Pten inactivation and the emergence of androgen-independent prostate cancer. Cancer Res., 67, 6535-6538.
3. Manning, B.D. and Cantley, L.C. $(2007) AKT/PKB signaling: navigating downstream. Cell, 129, 1261-1274.
4. Cairns, P., Okami, K., Halachmi, S., Halachmi, N., Esteller, M., Herman, J.G., Jen, J., Isaacs, W.B., Bova, G.S. and Sidransky, D. $(1997) Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res., 57, 4997-5000.
5. Yoshimoto, M., Cutz, J.C., Nuin, P.A., Joshua, A.M., Bayani, J., Evans, A.J., Zielenska, M. and Squire, J.A. $(2006) Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet. Cytogenet., 169, 128-137.
6. Taylor, B.S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B.S., Arora, V.K., Kaushik, P., Cerami, E., Reva, B. et al. $(2010) Integrative genomic profiling of human prostate cancer. Cancer Cell, 18, 11-22.
7. Sircar, K., Yoshimoto, M., Monzon, F.A., Koumakpayi, I.H., Katz, R.L., Khanna, A., Alvarez, K., Chen, G., Darnel, A.D., Aprikian, A.G. et al. $(2009) PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J. Pathol., 218, 505-513.
8. Verhagen, P.C., van Duijn, P.W., Hermans, K.G., Looijenga, L.H., van Gurp, R.J., Stoop, H., van der Kwast, T.H. and Trapman, J. $(2006) The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J. Pathol., 208, 699-707.
9. Mulholland, D.J., Tran, L.M., Li, Y., Cai, H., Morim, A., Wang, S., Plaisier, S., Garraway, I.P., Huang, J., Graeber, T.G. et al. $(2011) Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell, 19, 792-804.
10. Wang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G.V., Li, G., Roy-Burman, P., Nelson, P.S. et al. $(2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell, 4, 209-221.
11. Patient, R.K. and McGhee, J.D. $(2002) The GATA family (vertebrates and invertebrates). Curr. Opin. Genet. Dev., 12, 416-422.
12. Pandolfi, P.P., Roth, M.E., Karis, A., Leonard, M.W., Dzierzak, E., Grosveld, F.G., Engel, J.D. and Lindenbaum, M.H. $(1995) Targeted disruption of the GATA3 gene causes severe abnormalities in the nervous system and in fetal liver haematopoiesis. Nat. Genet., 11, 40-44.
13. Grigorieva, I.V., Mirczuk, S., Gaynor, K.U., Nesbit, M.A., Grigorieva, E.F., Wei, Q., Ali, A., Fairclough, R.J., Stacey, J.M., Stechman, M.J. et al. $(2010) Gata3-deficient mice develop parathyroid abnormalities due to dysregulation of the parathyroid-specific transcription factor Gcm2. J. Clin. Invest., 120, 2144-2155.
14. Grote, D., Boualia, S.K., Souabni, A., Merkel, C., Chi, X., Costantini, F., Carroll, T. and Bouchard, M. $(2008) Gata3 acts downstream of beta-catenin signaling to prevent ectopic metanephric kidney induction. PLoS Genet., 4, e1000316.
15. Grote, D., Souabni, A., Busslinger, M. and Bouchard, M. $(2006) Pax2/ 8-regulated Gata3 expression is necessary for morphogenesis and guidance of the nephric duct in the developing kidney. Development, 133, 53-61.
16. Lim, K.C., Lakshmanan, G., Crawford, S.E., Gu, Y., Grosveld, F. and Engel, J.D. $(2000) Gata3 loss leads to embryonic lethality due to noradrenaline deficiency of the sympathetic nervous system. Nat. Genet.,25, 209-212.
17. Raid, R., Krinka, D., Bakhoff, L., Abdelwahid, E., Jokinen, E., Karner, M., Malva, M., Meier, R., Pelliniemi, L.J., Ploom, M. et al. $(2009) Lack of Gata3 results in conotruncal heart anomalies in mouse. Mech. Dev., 126, 80-89.
18. Van Esch, H., Groenen, P., Nesbit, M.A., Schuffenhauer, S., Lichtner, P., Vanderlinden, G., Harding, B., Beetz, R., Bilous, R.W., Holdaway, I. et al. $(2000) GATA3 haplo-insufficiency causes human HDR syndrome. Nature, 406, 419-422.
19. Murphy, K.M. and Reiner, S.L. $(2002) The lineage decisions of helper T cells. Nat. Rev. Immunol., 2, 933-944.
20. Asselin-Labat, M.L., Sutherland, K.D., Barker, H., Thomas, R., Shackleton, M., Forrest, N.C., Hartley, L., Robb, L., Grosveld, F.G., van der Wees, J. et al. $(2007) Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat. Cell. Biol., 9, 201-209.
21. Kouros-Mehr, H., Slorach, E.M., Sternlicht, M.D. and Werb, Z. $(2006) GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell, 127, 1041-1055.
22. Dydensborg, A.B., Rose, A.A., Wilson, B.J., Grote, D., Paquet, M., Giguere, V., Siegel, P.M. and Bouchard, M. $(2009) GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis. Oncogene, 28, 2634-2642.
23. Kouros-Mehr, H., Bechis, S.K., Slorach, E.M., Littlepage, L.E., Egeblad, M., Ewald, A.J., Pai, S.Y., Ho, I.C. and Werb, Z. $(2008) GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell, 13, 141-152.
24. Perez-Stable, C.M., Pozas, A. and Roos, B.A. $(2000) A role for GATA transcription factors in the androgen regulation of the prostate-specific antigen gene enhancer. Mol. Cell Endocrinol., 167, 43-53.
25. Trotman, L.C., Niki, M., Dotan, Z.A., Koutcher, J.A., Di Cristofano, A., Xiao, A., Khoo, A.S., Roy-Burman, P., Greenberg, N.M., Van Dyke, T. et al. $(2003) Pten dose dictates cancer progression in the prostate. PLoS Biol., 1, E59.
26. Lapointe, J., Li, C., Higgins, J.P., van de Rijn, M., Bair, E., Montgomery, K., Ferrari, M., Egevad, L., Rayford, W., Bergerheim, U. et al.$ (2004) Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl Acad. Sci. USA, 101, 811-816.
27. Luo, J., Duggan, D.J., Chen, Y., Sauvageot, J., Ewing, C.M., Bittner, M.L., Trent, J.M. and Isaacs, W.B. $(2001) Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res., 61, 4683-4688.
28. Varambally, S., Yu, J., Laxman, B., Rhodes, D.R., Mehra, R., Tomlins, S.A., Shah, R.B., Chandran, U., Monzon, F.A., Becich, M.J. et al. $(2005) Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell, 8, 393-406.
29. Zhao, L. and Vogt, P.K. $(2008) Class I PI3K in oncogenic cellular transformation. Oncogene, 27, 5486-5496.
30. Karakas, B., Bachman, K.E. and Park, B.H. $(2006) Mutation of the PIK3CA oncogene in human cancers. Br. J. Cancer, 94, 455-459.
31. Kang, S., Denley, A., Vanhaesebroeck, B. and Vogt, P.K.$ (2006) Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc. Natl Acad. Sci. USA, 103, 1289-1294.
32. Wu, X., Wu, J., Huang, J., Powell, W.C., Zhang, J., Matusik, R.J., Sangiorgi, F.O., Maxson, R.E., Sucov, H.M. and Roy-Burman, P.$ (2001) Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech. Dev., 101, 61-69.
33. Nyabi, O., Naessens, M., Haigh, K., Gembarska, A., Goossens, S., Maetens, M., De Clercq, S., Drogat, B., Haenebalcke, L., Bartunkova, S. et al. $(2009) Efficient mouse transgenesis using Gateway-compatible ROSA26 locus targeting vectors and F1 hybrid ES cells. Nucleic Acids Res., 37, e55.
34. Uetani, N., Bertozzi, K., Chagnon, M.J., Hendriks, W., Tremblay, M.L. and Bouchard, M. $(2009) Maturation of ureter-bladder connection in mice is controlled by LAR family receptor protein tyrosine phosphatases. J. Clin. Invest., 119, 924-935.
35. Diallo, J.S., Aldejmah, A., Mouhim, A.F., Peant, B., Fahmy, M.A., Koumakpayi, I.H., Sircar, K., Begin, L.R., Mes-Masson, A.M. and Saad, F.$ (2007) NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model. Clin. Cancer Res., 13, 7044-7052.